GIP and type 2 diabetes mellitus: Tirzepatide is a co-agonist of the GIP and GLP-1 receptor, which was designed to improve glycemic control and aid in weight loss for T2D and obesity (Rosenstock et al., 2021; Wadden et al., 2023).